AUTO-8 is a gene-modified cell therapy commercialized by Autolus Therapeutics, with a leading Phase I program in Relapsed Multiple Myeloma. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of AUTO-8’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for AUTO-8 is expected to reach an annual total of $6 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

AUTO-8 Overview

AUTO-8 is under development for the treatment of relapsed and refractory multiple myeloma. The drug candidate is a retroviral vector that comprises T cells genetically engineered to express chimeric antigen receptors (CAR's) targeting BCMA and CD19. The drug candidate is a next-generation version. It is administered through parenteral route.

Autolus Therapeutics Overview

Autolus Therapeutics (Autolus) is a clinical-stage biopharmaceutical company. It offers programmed T-cell therapies for the treatment of hematological cancers and solid tumors. Autolus pipeline products include Obe-cel, AUTO1/22, AUTO5, AUTO6NG, AUTO7 and AUTO8. The company applies its extensive cell programming capability to develop a pipeline of precise, controlled and highly active products as it is both safe and the most therapeutically effective approach to manufacturing CAR T cells. Autolus is headquartered in London, England, the UK.
The company reported revenues of (US Dollars) US$1.7 million for the fiscal year ended December 2023 (FY2023), a decrease of 73.3% over FY2022. The operating loss of the company was US$179.7 million in FY2023, compared to an operating loss of US$143.4 million in FY2022. The net loss of the company was US$208.4 million in FY2023, compared to a net loss of US$148.8 million in FY2022.

For a complete picture of AUTO-8’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 22 April 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.